This "trumpeting" may also partially explain the observed use of more Xience stents per lesion compared to Resolute (1.18Ϯ0.45 vs. 1.15Ϯ0.42, pϭ0.02) in the Resolute All Comers (RAC) trial. The primary cause for secondary stenting in RAC was "to stabilize target lesion" which includes procedural complications including dissection or perforations.
All patients also underwent evaluation for secondary endpoints which included a Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents were also assessed for angiographic endpoints at 9 months including: in-stent and in-segment LLL. A subset of patients underwent IVUS evaluation including percent neointimal obstruction at 9 months. The study met the non-inferiority endpoint and also demonstrated superiority of the DESyne CSS as compared to control. Results: Table 1 summarizes 9-month angiographic and IVUS results and clinical results through 2 years which trend lower for the DESyne stent. 
Conclusions:
The study met the non-inferiority endpoint and also demonstrated superiority of the DESyne CSS as compared to control. Clinical results through 3 years and a review of angiographic and IVUS results will be presented.
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